Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Haematologica|June 26, 2025
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with BCR::ABL1-negative B-cell / myeloid mixed phenotype acute leukemiaRoberta S Azevedo, Wei-Ying Jen, Danielle Hammond, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 1, 2011
Targeting the bone marrow in Waldenstrom macroglobulinemiaIrene M Ghobrial, Yong Zhang, Yang Liu, et al.
Genes|March 28, 2025
Cryptic KMT2A::AFDN Fusion Due to AFDN Insertion into KMT2A in a Patient with Acute Monoblastic LeukemiaQing Wei, Gokce A Toruner, Beenu Thakral, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Nature Communications|October 22, 2021
Calibration-free NGS quantitation of mutations below 0.01% VAFPeng Dai, Lucia Ruojia Wu, Sherry Xi Chen, et al.
Frontiers in Oncology|February 2, 2026
Case Report: FIA plus venetoclax in a patient on hemodialysisJacob E Herstein, Kayleigh R Marx, J Michael Savoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2011
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's MacroglobulinemiaAntonio Sacco, Monette Aujay, Brittany Morgan, et al.
Cytometry. Part B, Clinical Cytometry|December 29, 2021
Comprehensive immunophenotypic study of acute myeloid leukemia with KMT2A (MLL) rearrangement in adults: A single-institution experienceSergej Konoplev, Xiaoqiong Wang, Guilin Tang, et al.
American Journal of Hematology|August 28, 2024
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemiaWei-Ying Jen, Elias Jabbour, Nicholas J Short, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 9, 2025
Unusually Indolent CML: Absence of Complete Cytogenetic Response after 10 Years of Tyrosine Kinase Inhibitor TherapyQiudan Shen, Fadi G Haddad, Elias J Jabbour, et al.
Pageof 16